Acrux Limited (ARUXF)

OTCMKTS · Delayed Price · Currency is USD

0.0169

+0.0002 (1.20%)

At close: Jun 3, 2026

-57.75% (1Y)

Market Cap	4.96M -18.5%
Revenue (ttm)	1.87M +250.4%
Net Income	-1.57M
EPS	-0.00
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	40,000
Open	0.0169
Previous Close	0.0167
Day's Range	0.0169 - 0.0169
52-Week Range	0.0010 - 0.0504
Beta	0.99
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 27, 2026

About Acrux

Acrux Limited, together with its subsidiaries, develops and commercializes generic and topically applied pharmaceutical products in Australia, Europe, the United States, and internationally. The company provides estradiol transdermal sprays to women for the treatment of flushes associated with menopause under the Evamist and Lenzetto brand names; Dapsone 5% and Dapsone 7.5%, which are gels for the treatment of acne vulgaris; and Lidocaine and Prilocaine Cream USP, a topical anesthetic cream. It is also involved in the development of Efinaconazo... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 1998

Employees 43

Stock Exchange OTCMKTS

Ticker Symbol ARUXF

Financial Performance

In fiscal year 2025, Acrux's revenue was 1.19 million, a decrease of -76.63% compared to the previous year's 5.09 million. Losses were -5.95 million, 2.50% more than in 2024.

Financial numbers in AUD Financial Statements